Total Funding
32
62
Total FundingPost-IPO Equity raised
Growth Score 32 in past quarter
-11 pts
Heat Score 62 in past quarter
21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
170869
Elite Pharmaceuticals develops oral controlled-release products for the pain management, allergy, cardiovascular, and infection areas.
John Moore: ChairmanPast Role: Acorn Energy, Director and CEO- Barry Dash: Director
About the Company
Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders. The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

